Newron Pharmaceuticals SPA
Evenamide 15 mg bid
Treatment-resistant Schizophrenia
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Evenamide 15 mg bid in Treatment-resistant Schizophrenia are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07184619: Phase 3 trial, sponsor Newron Pharmaceuticals SPA, drug Evenamide 15 mg bid. Primary completion date 2026-12-31 (estimated).”